Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES De Bono JS, Oudard S, Ozguroglu M, et al, “Cabazitaxel or Mitoxantrone With Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel: Final Results of a Multinational Phase III Trial (TROPIC),” J Clin Oncol , 2010, 28(7s):4508 [abstract 4508 from 2010 ASCO Annual Meeting] Mita AC, Denis LJ, Rowinsky Ek, et al, “Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Tumors, Clin Cancer Res , 2009, 15(2):723-30. [PubMed 19147780 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Prostate Cancer,” Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Sartor AO, Oudard S, Ozguroglu M, et al, “Cabazitaxel or Mitoxantrone With Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel: Final Results of a Multinational Phase III Trial (TROPIC),” 2010:9 [abstract 9 from 2010 ASCO Genitourinary Cancers Symposium] Topic 15577 Version 37.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.3 - C21.34 Licensed to: Morehouse School of Medicine | Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]